Louise St. Germain Bannon: Turning Thrombosis Awareness into Stroke Prevention
Louise St. Germain Bannon, Interim Executive Director at International Society on Thrombosis and Haemostasis (ISTH), shared a post on LinkedIn:
“After more than a decade working in thrombosis awareness and global health advocacy, one thing remains clear to me: Advancing science is essential, but translating that knowledge into prevention is what saves lives.
On WorldStrokeDay, I’m reminded of the critical connection between thrombosis and stroke, particularly atrial fibrillation (AFib), which increases stroke risk approximately fivefold.
Too often, AFib goes undetected until a serious complication occurs.
Through my work with the International Society on Thrombosis and Haemostasis (ISTH), I’ve seen firsthand the power of scientific collaboration, global advocacy and education to improve patient outcomes.
Our challenge isn’t simply to raise awareness.
It’s to turn awareness into action, research into policy, and knowledge into prevention.
Because behind every statistic is a life we have the opportunity to protect!”
Stay updated with Hemostasis Today.
-
Oct 30, 2026, 12:36Aryabhatta Sadhu: Sickle Cell Crisis Recognising When Treatment Must Change
-
Oct 30, 2026, 12:22Fabrice Cognasse: The Future of Blood Banks From Transfusion Support to Precision Medicine
-
Oct 30, 2026, 12:09Carmelo Gurnari: Clonal Dynamics in the Bone Marrow During Sepsis and Emergency Haematopoiesis
-
Oct 30, 2026, 11:49Advancing Global Care for Hemophilia and Bleeding Disorders – World Federation of Hemophilia
-
Oct 30, 2026, 05:18Flora Peyvandi: Molecular and Lab Markers Linked to Bleeding Severity in Factor VII Deficiency
-
Oct 30, 2026, 05:11Rana Al-Hrout: Exploring Approach to Macrocytic Anemia
-
Oct 30, 2026, 04:22Francisco Chacón-Lozsán: Acute Pulmonary Embolism in 2026 – Blood Pressure Is Not the Same as Perfusion
-
Oct 30, 2026, 04:15Samin Mohsenian: Launching the PRO-RBDD-FX Registry for Rare Coagulation Factor X Deficiency
-
Oct 30, 2026, 03:59Emil List Larsen: Identifying SERPINC1 Variants and Limitations of Routine Antithrombin Testing